Exendin analog formulations

Details Exendin analog formulations Exendin analog formulations

2005-11-10

2008-07-15

Bragdon, Kathleen Kerr (Department: 1656)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S278100, C514S002600, C514S003100, C514S012200, C530S300000

Reexamination Certificate

active

07399489

ABSTRACT:
Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

REFERENCES:
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 5839443 (1998-11-01), Rose et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6376549 (2002-04-01), Fine et al.
patent: 4179337 (2002-07-01), Frank et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 199731732 (1998-01-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/40788 (1999-08-01), None
patent: WO 00/41546 (2000-07-01), None
patent: WO 00/41548 (2000-07-01), None
Byrne, M.M., et al., “Lessons from Human Studies with Glucagon-like Peptide-1: Potential of the Gut Hormone for Clinical Use,” Front. Diabetes, 13:219-33(1997).
Chen, Y.E., et al., “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,”Journal of Biological Chemistry, 272(7): 4108-4115 (1997).
Creutzfeldt, W.O.C., et al., “Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-like Peptide I(7-36) Amide in Type I Diabetic Patients,”Diabetes Care19(6):580-6 (1996).
D'Alessio, et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38 (1996).
Egan, J.M., et al., “Glucagon-like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,”Diabetologia, 40 (Supp 1) :A130 abstract 505 (1997).
Daniel, O. et al., “Use of Glucagon in the Treatment of Acute Diverticultis,”British Medical Journal, 3:720-2, (1974).
Eissele, et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,”Life Sci., 55(8):629-34 (1994).
Eng, J., et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265(33):20259-62 (1990).
Eng, J., et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,” J. Biol. Chem., 267(11):7402-05 (1992).
Eng, J., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,”Diabetes, 45(Supp 2):152A (abstract 554) (1996).
Francis, et al., “PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques,”International Journal of Hematology, 68(1):1-18(1998).
Glauser, et al., “Intravenous Glucagon in the Management of Esophageal Food Obstruction,”JACEP, 8:228-231(1979).
Goke, et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem., 268(26):19650-55 (1993).
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma SuspectumVenom, Potentiates Cholecystokinin-Induced Amylase Release from Rat Pancreatic Acini,”Regulatory Peptides, 41:149-56 (1992).
O'Halloran, et al., “Glucagon-like Peptide-1 (7-36) -NH2: A Physiological Inhibitor of Gastric Acid Secretion in Man,”J. Endocrinol. 126(1):169-73 (1990).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes, 42:658-61 (1993).
Passa, P., et al., “Mechanisms Suppressing Glucagon Secretion in Glucagonomas,”Diabetologia, 19(3):305 [abstract 298] (1980).
Raufman, et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 267(30):21432-37 (1992).
Schepp, et al., “Exendin-4 and Exendin-(9-39)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm., 269:183-91 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis. Sci., 34(5):703-8 (1989).
Singh, et al., “Use of125I-[Y39]exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig,”Regul. Pep., 53:47-59 (1994).
Stower, et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,”Br. J. Surg., 69:591-2 (1982).
Thorens, “Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,”Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Turton, M.D., et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,”Nature, 379:69-72 (1996).
Wettergren, et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig. Dis. Sci., 38(4):665-73 (1993).
Willms, et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).
Bloom Sr, Polak JM. “Glucagonoma Syndrome.” Am J Med . 1987; 82:25-36.
Carlsson A, Sundkvist G, Groop L, Tuomi T. “Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA).” J Clin Endocrinol Metab. 2000; 85:76-80.
Drucker DJ. “Glucagon-like Peptides.” Diabetes. 1998;47:159-169.
Holst JJ. “Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors.” Expert Opin Emerg Drugs. 2004; 9:155-166.
Varshavsky A. “The Ubiquitin System.” Trends Biochem Sci. 1997; 22:383-7.
Markletter, ISSN: 0951-3175, (Aug. 24, 1998).
Parkes DG, Pittner R, Jodka C, Smith P, Young A. “Insulinotropic Actions of Exendin-4 and Glucagon-like Peptide-1 In Vivo and In Vitro.” Metabolism. 2001;50:583-589.
Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H. “Role of Organic Anion Transporter 1 (OAT1) in Cephaloridine (CER)-Induced Nephrotoxicity.” Kidney Int. 1999;56:2128-2136.
Lefebvre et al. (1979) Glucagon and diabetes: a reappraisal. Diabetologia, vol. 18, No. 6, pp. 347-354.
Delgado et al. (1979) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. vol. 9, issues 3-4, pp. 249-304.

Affiliated with

Also associated with

Rating

Exendin analog formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendin analog formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin analog formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3973338